financetom
Business
financetom
/
Business
/
Brown-Forman Fiscal Q4 Earnings, Net Sales Fall
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Brown-Forman Fiscal Q4 Earnings, Net Sales Fall
Jun 5, 2025 5:38 AM

08:26 AM EDT, 06/05/2025 (MT Newswires) -- Brown-Forman (BF.A, BF.B) reported fiscal Q4 earnings Thursday of $0.31 per share, down from $0.56 a year earlier.

Analysts polled by FactSet expected $0.33.

Net sales for the quarter ended April 30 were $894 million, down from $964 million a year earlier.

Analysts surveyed by FactSet expected $965.8 million.

Shares of the wine and spirits company were down more than 7% in recent Thursday premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Amicus Therapeutics Swings to Q2 Non-GAAP Net Income as Sales Rise; 2024 Revenue Growth Guidance Lifted
Amicus Therapeutics Swings to Q2 Non-GAAP Net Income as Sales Rise; 2024 Revenue Growth Guidance Lifted
Aug 8, 2024
08:36 AM EDT, 08/08/2024 (MT Newswires) -- Amicus Therapeutics ( FOLD ) reported Q2 non-GAAP net income Thursday of $0.06 per diluted share, swinging from a loss of $0.07 a year earlier. Analysts polled by Capital IQ expected normalized earnings of $0.02. Sales for the quarter ended June 30 were $126.7 million, up from $94.5 million a year earlier. Analysts...
Burford Capital Swings to Q2 Profit, Revenue Rises
Burford Capital Swings to Q2 Profit, Revenue Rises
Aug 8, 2024
08:36 AM EDT, 08/08/2024 (MT Newswires) -- Burford Capital ( BUR ) reported Q2 net income Thursday of $0.24 per diluted share, swinging from a loss of $0.10 a year earlier. An analyst polled by Capital IQ expected earnings per share of $0.34. Revenue for the quarter ended June 30 was $159.7 million, up from $44.6 million a year earlier....
Viagra-maker Viatris beats Q2 estimates on branded and generic drug demand
Viagra-maker Viatris beats Q2 estimates on branded and generic drug demand
Aug 8, 2024
Aug 8 (Reuters) - Drugmaker Viatris beat second-quarter profit and revenue estimates on Thursday, driven by strong demand for the Viagra-maker's off-patent branded and generic drugs. Shares of the company were up 3.6% in premarket trade. The Canonsburg, Pennsylvania-based company also raised the 2024 sales outlook for its new product range, including Breyna - a biosimilar to Astrazeneca's ( AZN...
Erdene Resource Says Bayan Khundii Development on Schedule, Q2 Net Loss Narrows
Erdene Resource Says Bayan Khundii Development on Schedule, Q2 Net Loss Narrows
Aug 8, 2024
08:36 AM EDT, 08/08/2024 (MT Newswires) -- Erdene Resource Development ( ERDCF ) on Thursday said that construction of the Bayan Khundii Gold Project in Mongolia is 30% complete and remains on schedule with first gold production expected in mid-2025. Recent exploration has also identified several new gold targets and drilling is underway at Bayan Khundii to test targets west...
Copyright 2023-2026 - www.financetom.com All Rights Reserved